Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C2) in heart transplant patients receiving anti-thymocyte globulin induction

Clinical Transplantation

Volumn 18, Issue 2, 2004, Pages 148-151

  Cantarovich, Marcelo ^a   Giannetti, Nadia ^a   Cecere, Renzo ^b  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Anti thymocyte globulin; C2 levels; Cyclosporine; Endomyocardial biopsy; Heart transplantation

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

ANTILYMPHOCYTE SERUM; BIOPSY, NEEDLE; CYCLOSPORINE; ENDOCARDIUM; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYOCARDIUM;

EID: 1642524473     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1399-0012.2003.00138.x     Document Type: Review

References (15)

1. Valantine H. Neoral use in the cardiac transplant recipient. Transplant Proc 2000: 32: 27S.
2. El Gamel A, Keevil B, Rahman A, Campbell C, Deiraniya A, Yonan N. Cardiac allograft rejection: Do trough cyclosporine levels correlate with the grade of histologic rejection? J Heart Lung Transplant 1997: 16: 268.
3. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two hour Cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 1998: 12: 243.
4. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels vs. 2-hr postdose levels in stable liver transplant patients. Transplantation 1998: 12: 1621.
5. max) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation 1999: 67: 1133.
6. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002: 2: 148.
7. 2). Transplantation 2002: 73: 953.
8. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002: 2: 157.
9. Cantarovich M, Elstein E, de Varennes B, Barkun J. Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour post dose levels compared to trough levels in stable heart transplant patients. Transplantation 1999: 68: 1839.
10. Cantarovich M, Latter D, Fitchett D. Cyclosporine A trough levels, acute rejection and renal dysfunction after heart transplantation. Transplantation 1995: 59: 444.
11. Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990: 6: 587.
12. Zuckermann AO, Grimm M, Czerny M et al. Improved long-term results with thymoglobuline induction therapy after cardiac transplantation: A comparison of two different rabbit-antithymocyte globulines. Transplantation 2000: 69: 1890.
13. Carrier M, White M, Perrault LP et al. A 10-year experience with intravenous thymoglobuline in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999: 18: 1218.
14. Eisen HJ, Hobbs RE, Davis SF et al. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine: Results at six months after transplantation. Transplantation 1999: 68: 663.
15. Eisen HJ, Hobbs RE, Davis SF et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine: Results at 24 months after transplantation. Transplantation 2001: 71: 70.